This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anis, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anis, A. H.
Related Collections
Right arrow Regulation
Right arrow Canadian government
CMAJ • February 22, 2000; 162 (4)
© 2000 Canadian Medical Association or its licensors

Review
Synthèse

Pharmaceutical policies in Canada: another example of federal-provincial discord

Aslam H. Anis

From the Department of Health Care and Epidemiology, University of British Columbia, and the Center for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, BC

Abstract

Pharmaceutical policy in Canada is set at both the federal and provincial levels of government. The federal government is responsible for intellectual property rights of manufacturers (patents) and the initial approval and labelling of prescription drugs and for ensuring overall market competitiveness. The provincial government has responsibility and jurisdiction over the funding of all health care services, including pharmaceuticals. Various interactions between the pharmaceutical industry, the federal and provincial governments and consumers have shaped the current landscape for prescription drugs in Canada. One key failing of the system is that the federal government is almost completely insulated from the impact of its policies because, although it regulates drug prices, it does not buy any drugs. In contrast, provincial governments have no jurisdiction over market competitiveness or pricing, yet end up paying for most of the drug expenditures incurred.




This article has been cited by other articles:


Home page
 CMAJHome page
K. G. Shojania
Safe prescribing
Can. Med. Assoc. J., January 2, 2007; 176(1): 66 - 67.
[Full Text] [PDF]